On September 22, 2023, the World Federation of Chinese Doctors and Baheal Pharmaceutical Group jointly initiated the 2023 World Chinese Physicians Conference and the Medical Innovation and Translation Forum in Qingdao, Shandong. This gathering, the first grand ceremony since the pandemic, brought together numerous exceptional representatives of Chinese doctors and scholars from both home and abroad to share the latest accomplishments and innovative trends in global healthcare. As a critical part of this forum, the Baheal Pharmaceutical Group, witnessed by a multitude of experts and academics, signed a contract with Professor Wang Wei, the Vice President of the World Federation of Chinese Doctors and Deputy Principal of Edith Cowan University (ECU) in Australia. They will collaborate to establish a research platform in the realm of glycomics.

On August 21, 2023, Qingdao Baheal Pharmaceutical Co., Ltd. (referred to as "Baheal Pharmaceutical", 301015.SZ) and Gilead (Shanghai) Pharmaceutical Technology Co., Ltd. (referred to as "Gilead Sciences") signed a strategic cooperation agreement. Representatives from both companies, including Jin Fangqian, Global Vice President and General Manager of Gilead Sciences China, and Fu Gang, Chairman of Baheal Pharmaceutical, attended the signing ceremony.

On June 13, 2023, the second "West Beijing Development Forum" themed "Transforming and Nurturing New Opportunities: focus on West Beijing" was held in Shijingshan District, Beijing, at the Shougang Park. Attendees of the forum were guests from the government, corporate organizations, and authoritative media, who participated in discussions and dialogues, jointly discussing the high-quality transformation of West Beijing. The forum showcased the achievements of the region's industrial transformation in recent years and it also included a series of strategic collaborations and project signings. Over 60 enterprises, including Baheal Pharmaceutical Group and its nurtured high-end medical equipment enterprise, Huake Pioneer, signed various agreements with the "two districts and two enterprises" (Shijingshan District and Mentougou District, Shougang Group and Jingneng Power Co., Ltd) for strategic cooperation, company settlement, and project landing.

On June 11, 2023, Baheal Medical and RabPharma have embarked on a strategic collaboration focused on the commercialization of RAB001 injection (known as "RAB001"), a first-in-class innovative drug for osteonecrosis, within mainland China.

Baheal Pharma Group partnered with Peking Union Medical College Education Foundation to establish a ten-year donation project, totaling 5 million yuan, to support talent cultivation, scientific research innovation, and practice at the Institute of Systems Medicine, Chinese Academy of Medical Sciences.